| |
Monday, December 16, 2024 | 1pm ET / 10am PT Join us for an insightful webinar on the evolving privacy landscape impacting pharma marketers. As state laws continue to shape advertising practices, understanding the nuances of compliance and data ethics is crucial. Register now to gain access to expert insights on sustainable privacy strategies and balancing innovation with ethical data use. 
|
|
| By Nick Paul Taylor LinkedIn likes have landed drugmakers in trouble once again. AstraZeneca—a repeat offender—and GSK were the subjects of the investigations under the U.K. marketing code, which found the companies broke the rules on promoting prescription medicines to the public. |
|
|
|
By Nick Paul Taylor Merck & Co. has shown off data on its ROR1-directed antibody-drug conjugate, trumpeting a 100% complete response rate but also reporting safety signals that informed the decision to take the low dose into phase 3. |
By Zoey Becker The executives attended a dinner at the President-elect's Mar-a-Lago residence to discuss topics such as finding cures for cancer through private and public sector collaboration, Axios reports. |
By Kevin Dunleavy One of the keys to cutting the cost of drugs in the United States is to raise their cost in other countries, Eli Lilly CEO David Ricks said Tuesday in an interview at the Economic Club of Washington, D.C. |
By Conor Hale Donald Trump has named tech investor David Sacks to be “A.I. & Crypto Czar” as a newly created role in his administration next year, to help guide its approaches toward artificial intelligence. |
By Nick Paul Taylor AbbVie has completed a hat trick of phase 3 wins for its Parkinson’s disease prospect tavapadon, teeing the drugmaker up to file for FDA approval of drug candidate in 2025. |
By Darren Incorvaia Chroma Medicines and Nvelop Therapeutics are fusing their names and science to launch nChroma Bio along with the backing of a $75 million fundraising round led by Cormorant Asset Management, Arch Venture Partners, Atlas Venture and Newpath Partners. |
By Zoey Becker The share buyback program comes after a recent $5 billion buyback campaign the company completed during the current quarter. |
By Darren Incorvaia Capsida Biotherapeutics has unveiled data showing that its AAV-delivered gene therapy for developmental and epileptic encephalopathy (DEE), the most severe form of epilepsy, corrected cognitive and motor deficits and reduced seizures in mice up to one year after treatment. |
By Joseph Keenan The Vertex agreement is part of the Saudi Kingdom’s plan to make itself a global biotech hub by 2040. |
Fierce podcasts Don’t miss an episode |
| Anastassia Gliadkovskaya speaks to Nichole Sweeney, general counsel and chief privacy officer of the state’s designated HIE, CRISP Shared Services, about Maryland's new law to protect sensitive patient data from interstate exchange. |
|
|---|
|
|
|
Wednesday, January 15, 2025 | 12pm ET / 9am PT Sort through the noise and hear from Washington Insiders. This session will offer key insights into the economic and political landscape, guiding your company on how best to prepare for and respond to potential changes in funding opportunities and compliance requirements. Register now. 
|
|
Research Read this case study to discover how programmatic EHR advertising can transform your omnichannel marketing strategy. Sponsored by: Veradigm |
Whitepaper Explore the robust cross-platform agreement between scRNA-seq and bulk RNA-seq, ensuring consistent and reproducible data on immune cell presence. Sponsored by: IQVIA Laboratories |
Whitepaper Learn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
Whitepaper We interviewed 14 R&D biopharma leaders on the critical success factors for building a Best Practice R&D organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
Research Read this case study to discover how programmatic EHR advertising can transform your omnichannel marketing strategy. Sponsored by: Veradigm |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
+(1).png)
